Ingalls & Snyder LLC’s GSK GSK Stock Holding History

Ingalls & Snyder LLC’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$909K	Hold	16,472	–	–	0.03%	227
2025 Q4	$808K	Sell	16,472 -47	-0.3%	-$2.19K	0.03%	239
2025 Q3	$713K	Sell	16,519 -2,500	-13%	-$97.7K	0.02%	260
2025 Q2	$730K	Sell	19,019 -160	-0.8%	-$6.11K	0.03%	254
2025 Q1	$743K	Sell	19,179 -136	-0.7%	-$4.98K	0.02%	251
2024 Q4	$653K	Sell	19,315 -8,340	-30%	-$300K	0.03%	260
2024 Q3	$1.13M	Sell	27,655 -352	-1%	-$14.4K	0.04%	213
2024 Q2	$1.08M	Sell	28,007 -640	-2%	-$26.9K	0.05%	209
2024 Q1	$1.23M	Buy	28,647 +1,600	+6%	+$66K	0.05%	195
2023 Q4	$1M	Sell	27,047 -3,848	-12%	-$138K	0.05%	212
2023 Q3	$1.12M	Buy	30,895 +2,253	+8%	+$80K	0.05%	198
2023 Q2	$1.02M	Buy	28,642 +1,480	+5%	+$53.1K	0.05%	209
2023 Q1	$966K	Buy	27,162 +542	+2%	+$19K	0.05%	215
2022 Q4	$935K	Sell	26,620 -16,052	-38%	-$535K	0.05%	209
2022 Q3	$1.26M	Sell	42,672 -7,089	-14%	-$269K	0.07%	171
2022 Q2	$2.71M	Sell	49,761 -2,200	-4%	-$121K	0.14%	116
2022 Q1	$2.83M	Sell	51,961 -2,000	-4%	-$109K	0.13%	124
2021 Q4	$2.98M	Sell	53,961 -2,736	-5%	-$142K	0.13%	129
2021 Q3	$2.71M	Sell	56,697 -5,497	-9%	-$276K	0.12%	137
2021 Q2	$3.1M	Sell	62,194 -1,520	-2%	-$73K	0.14%	130
2021 Q1	$2.84M	Buy	63,714 +40	+0.1%	+$1.82K	0.13%	127
2020 Q4	$2.93M	Sell	63,674 -2,241	-3%	-$103K	0.14%	120
2020 Q3	$3.1M	Buy	65,915 +5,720	+10%	+$287K	0.21%	88
2020 Q2	$3.07M	Sell	60,195 -1,040	-2%	-$53.4K	0.18%	102
2020 Q1	$2.9M	Buy	61,235 +720	+1%	+$38.4K	0.2%	96
2019 Q4	$3.56M	Buy	60,515 +5,273	+10%	+$293K	0.19%	99
2019 Q3	$2.95M	Sell	55,242 -356	-0.6%	-$18.3K	0.14%	119
2019 Q2	$2.78M	Buy	55,598 +300	+0.5%	+$15.1K	0.13%	122
2019 Q1	$2.89M	Buy	55,298 +440	+0.8%	+$22K	0.14%	125
2018 Q4	$2.62M	Sell	54,858 -440	-0.8%	-$21.7K	0.14%	126
2018 Q3	$2.78M	Buy	55,298 +12,527	+29%	+$636K	0.12%	138
2018 Q2	$2.15M	Buy	42,771 +516	+1%	+$26K	0.1%	144
2018 Q1	$2.06M	Buy	42,255 +1,100	+3%	+$51.2K	0.1%	148
2017 Q4	$1.82M	Sell	41,155 -5,829	-12%	-$269K	0.08%	162
2017 Q3	$2.38M	Sell	46,984 -647	-1%	-$32.8K	0.12%	121
2017 Q2	$2.57M	Sell	47,631 -183	-0.4%	-$9.76K	0.14%	110
2017 Q1	$2.52M	Sell	47,814 -2,000	-4%	-$101K	0.13%	115
2016 Q4	$2.4M	Sell	49,814 -912	-2%	-$45.1K	0.13%	123
2016 Q3	$2.73M	Buy	50,726 +6,960	+16%	+$382K	0.15%	108
2016 Q2	$2.37M	Sell	43,766 -1,528	-3%	-$80.5K	0.14%	114
2016 Q1	$2.29M	Buy	45,294 +400	+0.9%	+$19.9K	0.15%	109
2015 Q4	$2.26M	Buy	44,894 +5,184	+13%	+$264K	0.14%	107
2015 Q3	$1.91M	Sell	39,710 -6,374	-14%	-$332K	0.12%	113
2015 Q2	$2.4M	Sell	46,084 -31,298	-40%	-$1.76M	0.13%	113
2015 Q1	$4.46M	Buy	77,382 +2,081	+3%	+$119K	0.25%	78
2014 Q4	$4.02M	Buy	75,301 +2,970	+4%	+$166K	0.23%	80
2014 Q3	$4.16M	Sell	72,331 -16,825	-19%	-$1.03M	0.22%	79
2014 Q2	$5.96M	Buy	89,156 +2,088	+2%	+$141K	0.29%	68
2014 Q1	$5.82M	Buy	87,068 +2,392	+3%	+$162K	0.31%	64
2013 Q4	$5.65M	Buy	84,676 +2,264	+3%	+$147K	0.31%	60
2013 Q3	$5.17M	Sell	82,412 -3,090	-4%	-$199K	0.31%	61
2013 Q2	$5.34M	Buy	+85,502	New	+$5.43M	0.34%	61

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Ingalls & Snyder LLC's GSK Position: Q1 2026 in Review

Ingalls & Snyder LLC held its GSK (GSK) position steady in Q1 2026 at 16,472 shares worth $909K. The position accounts for 0.03% of the portfolio, ranked #227.

Ingalls & Snyder LLC first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.96M in Q2 2014. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Ingalls & Snyder LLC held 16,472 shares of GSK worth $909K as of Q1 2026.
Ingalls & Snyder LLC left its GSK share count unchanged in Q1 2026.
GSK made up 0.03% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #227 holding.
Ingalls & Snyder LLC first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
Ingalls & Snyder LLC's GSK position peaked at $5.96M in Q2 2014.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.